INFORMATION TECHNOLOGIES FOR EVALUATION OF SEVERITY AND MONITORING OF CHILDREN'S STATE WITH JUVENILE RHEUMATOID ARTHRITIS

  • O. P. Mintser Shupyk National Medical Academy of Postgraduate Education
  • T. Yu. Dubinina Shupyk National Medical Academy of Postgraduate Education
Keywords: information technology, rare diseases, juvenile rheumatoid arthritis, evaluation criteria, risks, monitoring.

Abstract

Systematization of the relevant data of quantitative monitoring of the population of children with rare (orphan) diseases remains a difficult problem. When assessing the severity of the pathological condition and monitoring the response to therapy, the criteria and indices of activity of juvenile rheumatoid arthritis are introduced. Such tools are necessary for choosing therapeutic programs, forecasting the course of the disease, and assessing the risks to the patient. Determining the set of data elements for mathematical modeling tasks is the primary stage of this process.

References

Mintser, O. P., Banchuk, M. V., & Kharik, N. V.

(2013). Priinyattya medichnikh rishen' v umovakh rizikiv viniknennya informatsiinoi ta tekhnologichnoi singulyarnosti [Medical decision making in the face of the risk of information and technological singularity]. Sistemi pidtrimki priinyattya rishen'. Teoriya i praktika (Decision Support Systems. Theory and Practice), 100-103.

Peay, H. L., Hollin, I., Fischer, R., & Bridges, J. F.

(2014). A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin. Ther., 36(5), 624-637. doi: 10.1016/j. clinthera.2014.04.011.

Albrecht, G. L., & Devlieger, P. J. (1999). The disability

paradox: high quality of life against all odds. Soc. Sci. Med., 48(8), 977-988.

Saag, K. G., Teng, G. G., Patkar, N. M., Anuntiyo, J., Finney, C., Curtis, J. R., Paulus, H. E, ... Furst, D. E. (2008). American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum., 59(6), 762-784. doi: 10.1002/ art.23721.

Coulson, E. J., Hanson. H. J. M., & Foster, H. E. (2014).

What does an adult rheumatologist need to know about juvenile idiopathic arthritis? Rheumatology, 53(12), 2155-2166. doi: 10.1093/rheumatology/keu257.

Jiang, G., Evans, J., Oniki, T. A., Coyle, J. F., Bain, L.,

Huff, S. M., Kush, R. D., & Chute, C. G. (2015). Harmonization of detailed clinical models with clinical study data standard. Methods Inf. Med., 54(1), 65-74. doi: 10.3414/ME13-02-0019.

Henrard S., & Arickx F. (2016). Negotiating prices of

drugs for rare diseases. Bull. World Health Organ., 94(10), 779-781. doi: 10.2471/BLT.15.163519.

Morèl, T., Aymé, S., Cassiman, D., Simoens, S., Morgan, M., & Vandebroek, M. (2016). Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J. Rare Dis., 11(1), 70. doi: 10.1186/s13023-016-0444-9.

Rodwell, C., & Aymé, S. (2015). Rare disease policies

to improve care for patients in Europe. Biochim. Biophys. Acta., 1852(10), 2329-2335. doi: 10.1016/j. bbadis.2015.02.008.

Forrest, C. B., Bartek, R. J., Rubinstein, Y., & Groft, S. C. (2011). The case for a global rare-diseases registry. The Lancet, 377(9771), 1057-1059. doi: 10.1016/S0140-6736(10)60680-0.

Taruscio, D., Mollo, E., Gainotti, S., Posada de la Paz. M., Bianchi, F., & Vittozzi, L. (2014). The EPIRARE proposal of a set of indicators and common data elements for the European platform for rare disease registration. Arch. Public Health, 72(1), 35. doi: 10.1186/20493258-72-35.

Published
2018-06-05
How to Cite
Mintser, O., & Dubinina, T. (2018). INFORMATION TECHNOLOGIES FOR EVALUATION OF SEVERITY AND MONITORING OF CHILDREN’S STATE WITH JUVENILE RHEUMATOID ARTHRITIS. Medical Informatics and Engineering, (1). https://doi.org/10.11603/mie.1996-1960.2018.1.8890
Section
Articles